19 September 2019
AfriAg Global
PLC
(‘AfriAg’ or the
‘Company’)
Grand Opening of Doc’s Place
International, Inc. (‘Doc’s Place’) and Apollon Formularies
Jamaica, Ltd. on 25 October.
Weekend Media
Release, Jamaica
AfriAg Global PLC, a company whose shares are admitted to
trading on London’s NEX Exchange, is pleased to announce that over
the past weekend in Jamaica
Apollon Formularies Jamaica, Ltd. notified the public that
the grand opening of the first Global Center for Medical Cannabis
Therapy will take place on 25th October 2019 in Negril, Jamaica at the facilities of Doc’s Place
International, Inc. Wired JA Online News released an article
on 14 September, announcing the opening
(http://www.wiredja.com/index.php?option=com_k2&view=item&id=10513:jamaica-jamaica-s-first-global-centre-for-medical-cannabis-therapy-opens-in-negril&Itemid=940&utm_source=newsletter_598&utm_medium=email&utm_campaign=in-wired-ja-news-today).
The opening ceremony will include a Keynote speech by the Jamaican
Minister of Commerce, Industry, Agriculture and Fisheries, the Hon.
Audley Shaw, whose responsibilities
include authority over the Cannabis Licensing Authority (CLA)
.
Apollon Formularies Jamaica. Ltd. also issued a media
release in Jamaica over the
weekend, stating that Jamaican legislation continues to create a
solid framework within which to operate as it now moves to
capitalise on the revenue earning potential and the further
advancement of medical knowledge of the medicinal cannabis space.
The Company beleives Apollon Formularies Jamaica, Ltd. sits
at the forefront of scientific endeavour in the medicial cannabis
space, with the opening of this state of the art, next generation
master-planned wellness and treatment facility as well as the most
modern and licenced processing and production facility in
Jamaica.
AfriAg Global’s relationship with
Apollon Formularies Ltd:
As previously announced, AfriAg completed an investment in
Apollon Formularies Ltd (“Apollon UK”) of 2.325 per cent of Apollon
UK's issued share capital and is in negotiations with Apollon
UK and a majority of its shareholders to acquire all the
issued and outstanding shares owned by shareholders. Further
investments in, or acquisition of, Apollon UK, are subject to
shareholder and regulatory approvals. Apollon UK is an
indirect investor in Apollon Formularies Jamaica, Ltd. and will
have the right to receive 95 percent of the net profit of Apollon
Formularies Jamaica, Ltd. Apollon UK also has a right to
acquire 90 percent of the issued and outstanding stock of Doc’s
Place International, Inc.
Apollon Formularies Jamaica, Ltd. and Doc’s Place have completed
a successful six-week pilot opening for the treatment of patients
which started on Thursday 1st August 2019, to coincide with Emancipation Day
and the start of the Jamaican tourist season.
The Doc’s Place facility which will have its official opening on
Friday 25th October 2019,
is a joint venture between Doc’s Place International, Inc., a
health and wellness resort, and Apollon Formularies Jamaica, Ltd.
It is located at Doc’s Place, Hotel and Resort Centre in Negril’s
West End.
The goal of the Medical Cannabis Therapy Centre is to provide an
environment that enhances the quality of life for those being
served. It is modelled on treatment centres, spas, resorts, and
hotels, that provide hospitality-oriented services in combination
with personal care and well-being services.
CEO of Doc’s Place and a director of Apollon Formularies
Jamaica, Ltd., Stephen D. Barnhill,
MD, said, “This strategic relationship provides patients worldwide
with the opportunity to receive world-class medical cannabis
treatments provided by licensed physicians with special expertise
in treating with medical cannabis-based pharmaceuticals in a safe,
professional, medical and legal environment.”
Commenting on the new facility, Medical Director of Doc’s Place
International, Inc. and a U.S. board-certified neurosurgeon,
Anthony Hall, MD, said, "We are very
excited about the opening of the world’s first Global Center
of Excellence for Medical Cannabis Therapy in Negril, Jamaica, which will provide patients with
specialized medical care for the myriad of conditions shown to be
beneficially treated with medical cannabis pharmaceuticals in a
Federally legal environment." Dr. Hall is supported by a team,
which includes Dr. Marjorie Vassell
and Dr. Alfred Dawes.
Chief Science Officer of Doc’s Place International and former
professor and director of Clinical Chemistry at MD Anderson Cancer
Centre, Herb Fritsche, Ph.D.,
pointed out: “Having the world’s first Global Center of
Excellence for Medical Cannabis Therapy gives us the opportunity to
do state-of-the-art research, clinical trials and development based
on patient outcomes data, create and adapt pharmaceutical
formulations, establish accurate therapeutic doses and develop
genomic markers to better determine the proper course of treatment
for patients being treated by our excellent medical team using
Apollon Formularies Jamaica, Ltd.’s award-winning medical cannabis
strains and cannabis-based pharmaceutical formulary.“
Paul Burke, CEO of Apollon
Formularies Jamaica, Ltd., said, “We are pleased that we have
a strategic relationship with Doc’s Place International to open the
world’s first Global Center of Excellence for Medical Cannabis
Therapy in Negril, Jamaica, and to
provide legal, state-of-the-art, quality-controlled medical
cannabis-based pharmaceuticals to the excellent medical team
treating these patients.”
Jamaica’s Ministry of Tourism has the development of health and
wellness tourism as one of its pillars for growing the tourism
industry, and the Ministry of Health and Wellness recently said
they hope to attract over 100,000 medical tourists to the island
within the next 10 years. Doc’s Place International’s Global Center
for Medical Cannabis Therapy aims to be a major contributor to this
increase in medical tourists to the island.
In their media publication over the weekend, Apollon Formularies
Jamaica, Ltd. stated that Medical Cannabis has been shown to be
beneficial in a myriad of conditions, including prostate cancer,
breast cancer, brain cancer, nausea/vomiting (chemotherapy),
nausea/vomiting (sea sickness), post traumatic stress disorder
(PTSD), chronic pain, arthritis, crohn’s disease/ulcerative
colitis, epilepsy, glaucoma, HIV, Alzheimer’s Disease, Lupus (SLE),
opioid/narcotic rehabilitation, Parkinson’s Disease, anxiety
disorders and sleep disorders.
Notice Regarding Forward-Looking
Statements
This announcement includes "forward-looking statements"
involving the Company, the other entities referenced in this
announcement, and the respective subsidiaries, affiliates and
associates of the Company and such other entities (collective, the
“Involved Entities”), which include all statements other than
statements of historical facts, including, without limitation,
those regarding the financial position, business strategy, plans
and objectives of management for future operations, and any
statements preceded by, followed by or that include forward-looking
terminology such as the words "targets", "believes", "estimates",
"expects", "aims", "intends", "will", "can", "may", "anticipates",
"would", "should", "could" or similar expressions or the negative
thereof. Such forward-looking statements involve known and unknown
risks, uncertainties and other important factors beyond the control
of the Involved Entities that could cause the actual results,
performance or achievements of the Involved Entities to be
materially different from future results, performance or
achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous
assumptions regarding the present and future business strategies of
the Involved Entities and the environment in which the Involved
Entities will operate in the future. These forward-looking
statements speak only as of the date of this announcement. The
Company, on behalf of itself and each of the Involved Entities,
expressly disclaims any obligation or undertaking to disseminate
any updates or revisions to any forward-looking statements
contained in this announcement to reflect any change in
expectations of any Involved Entities with regard thereto or any
change in events, conditions or circumstances on which any such
statements are based. As a result of these factors, readers are
cautioned not to rely on any forward-looking statement.
The directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information on AfriAg Global please visit the
www.afriagglobal.com or please contact;
AfriAg Global
Plc:
David Lenigas (Executive
Chairman)
+44 (0)20 7440 0640
Peterhouse Capital
Limited
+44 (0)20 7469 0930
Guy Miller/Allie Feuerlein
